New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=HYhfbgi-QGE

On www.xtalks.com - The US Food and Drug Administration (FDA) has approved Zejula (niraparib) as a maintenance treatment for women with certain types of recurrent cancers, including epithelial ovarian, fallopian tube, and primary peritoneal cancer. • To read more: http://xtalks.com/PARP-Inhibitor-Recu... • For more news stories, visit: http://xtalks.com/News.ashx • Receive weekly news updates right in your inbox: http://xtalks.com/subscribe.ashx • Listen live and interact with featured speakers on our upcoming Life Science webinars: http://xtalks.com/upcoming.ashx

#############################

New on site